Lymphotoxin-dependent control of long COVID
NIAID - National Institute of Allergy and Infectious Diseases
About This Grant
SARS-CoV-2 infection causes acute lung pathology and can lead to long-term complications, collectively known as long COVID. These complications include persistent pain, headaches, myalgia, and post-exertional malaise. However, the mechanisms behind these neurological symptoms remain poorly understood. In particular, the role of sensory neurons in the pathogenesis of long COVID is largely unexplored. This knowledge gap hinders the development of novel therapeutic strategies for managing neurological complications associated with long COVID. Animal models are essential for investigating the role of sensory neurons in SARS-CoV-2 infection and testing preclinical interventions. Unfortunately, existing mouse models that allow for the study of SARS-CoV-2 specific effects on sensory neurons in vivo are lacking. In our research, we found that wild-type mice infected with a mouse- adapted SARS-CoV-2 strain develop long-term pain. To further explore the role of sensory neurons in long COVID, we developed a mouse model with selective SARS-CoV-2 infection of sensory neurons through hACE2 expression in Nav1.8+ neurons. Additionally, we identified lymphotoxin beta receptor (LTβR) as a novel immune regulator of chronic pain following SARS-CoV-2 infection. The objective of this proposal is to investigate the role of LTβR signaling in sensory neurons in the pathogenesis of long COVID and to test the potential of LTβR antagonist to mitigate neurological complications of long COVID. Our central hypothesis is that LTβR signaling in sensory neurons promotes long COVID neurological symptoms which can be ameliorated by administration of LTβR antagonist. This hypothesis will be tested through two specific aims. In Aim 1, we will define the impact of LTβR signaling in sensory neurons on long COVID neurological symptoms, viral replication, and immune cell changes in sensory ganglia, using mice with selective LTβR inactivation in Nav1.8+ sensory neurons. In Aim 2, we will assess the therapeutic effects of LTβR antagonist in alleviating long COVID neurological symptoms and identify critical LTβR-dependent pathways in sensory ganglia using single-cell RNA sequencing. This proposal is innovative, significant and impactful, as it will elucidate the role of sensory neurons in long COVID pain, establish new animal models for studying long COVID, and evaluate the therapeutic potential of LTβR antagonists for treating SARS-CoV-2-induced neurological complications.
Grant Summary
Lymphotoxin-dependent control of long COVID is a NIAID - National Institute of Allergy and Infectious Diseases grant providing up to $235K for university, nonprofit, healthcare org. Applications are due 2028-01-31 (open). Check eligibility and apply with FindGrants.
Focus Areas
Eligibility
How to Apply
Up to $235K
2028-01-31
- 1Confirm your organization is eligible for Lymphotoxin-dependent control of long COVID from NIAID - National Institute of Allergy and Infectious Diseases, checking organization type, location, and any population or project requirements.
- 2Gather the required documents and information, including your organization details, project plan, and budget figures.
- 3Draft your application narrative and budget addressing the funder's priorities and review criteria. FindGrants can draft each section for you to review and edit.
- 4Review every section against the requirements checklist, then export a submission-ready application pack and submit it to NIAID - National Institute of Allergy and Infectious Diseases before the deadline.
Don't want to draft it yourself?
We'll draft the complete application against NIAID - National Institute of Allergy and Infectious Diseases's requirements, run a quality review, and email you a submission-ready PDF plus an editable Word doc within 5 business days. Most orders deliver in 24-48 hours. Flat $399, any grant size.
AI Requirement Analysis
Detailed requirements not yet analyzed
Have the NOFO? Paste it below for AI-powered requirement analysis.
Lymphotoxin-dependent control of long COVID: Frequently Asked Questions
Who is eligible for the Lymphotoxin-dependent control of long COVID?
Lymphotoxin-dependent control of long COVID is offered by NIAID - National Institute of Allergy and Infectious Diseases and is generally open to university, nonprofit, healthcare org. It is open to organizations nationwide unless the funder specifies otherwise. Review the specific eligibility terms before applying, since funders set their own requirements around organization type, location, and the population or project being served.
How much funding does the Lymphotoxin-dependent control of long COVID provide?
Lymphotoxin-dependent control of long COVID provides up to $235K per award from NIAID - National Institute of Allergy and Infectious Diseases. Actual award sizes depend on the scope of your project, available program funds, and the number of applicants, so build a budget that reflects realistic, allowable costs rather than the maximum figure.
When is the Lymphotoxin-dependent control of long COVID deadline?
Applications for Lymphotoxin-dependent control of long COVID are due 2028-01-31 (open). Because deadlines can change, verify the date with the funder, NIAID - National Institute of Allergy and Infectious Diseases, and give yourself enough time to prepare a complete, competitive application before the close date.
How do you apply for the Lymphotoxin-dependent control of long COVID?
To apply for Lymphotoxin-dependent control of long COVID, confirm your eligibility, gather the required documents, and prepare a narrative and budget that address the funder's priorities. FindGrants guides you step by step and can draft each section, then exports a submission-ready application pack for this grant from NIAID - National Institute of Allergy and Infectious Diseases.